Immune responses and reinfection of SARS‐CoV ‐2 Omicron variant in patients with lung cancer
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35038 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Chen Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Labo…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Lung Neoplasms, Antibodies, Viral. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
A significant Omicron wave emerged in China in December 2022. To explore the duration of humoral and cellular response postinfection and the efficacy of hybrid immunity in preventing Omicron reinfection in patients with lung cancer, a total of 447 patients were included in the longitudinal study after the Omicron wave from March 2023 to August 2023. Humoral responses were measured at pre‐Omicron wave, 3 months and 7 months postinfection. The detected severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) specific antibodies including total antibodies, anti‐receptor binding domain (RBD) specific IgG, and neutralizing antibodies against SARS‐CoV‐2 wild type (WT) and BA.4/5 variant. T cell responses against SARS‐CoV‐2 WT and Omicron variant were evaluated in 101 patients by ELISpot at 3 months postinfection. The results showed that Omicron‐infected symptoms were mild, while fatigue (30.2%), shortness of breath (34.0%) and persistent cough (23.6%) were long‐lasting, and vaccines showed efficacy against fever in lung cancer patients. Humoral responses were higher in full or booster vaccinated patients than those unvaccinated ( p < .05 for all four antibodies), and the enhanced response persisted for at least 7 months. T cell response to Omicron was higher than WT peptides (21.3 vs. 16.0 SFUs/10 6 PBMCs, p = .0093). Moreover, 38 (9.74%) patients were reinfected, which had lower antibody responses than non‐reinfected patients (all p < .05), and those patients of unvaccinated at late stage receiving anti‐cancer immunotherapy alone were at high risk of reinfection. Collectively, these data demonstrate the Omicron infection induces a high and durable immune response in vaccinated patients with lung cancer, which protects vaccinated patients from reinfection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Labor…
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Mengzhao Wang, Xiaohong Han
Förderung
- National High Level Hospital Clinical Research Funding
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Chen, C., Zhou, X., Gao, X., Pan, R., He, Q., Guo, X., Yu, S., Wang, N., Zhao, Q., Wang, M., Xu, Y., & Han, X. (2024). Immune responses and reinfection of SARS‐CoV ‐2 Omicron variant in patients with lung cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.35038
Vancouver
Chen C, Zhou X, Gao X, Pan R, He Q, Guo X, et al. Immune responses and reinfection of SARS‐CoV ‐2 Omicron variant in patients with lung cancer. International Journal of Cancer. 2024. doi:10.1002/ijc.35038
BibTeX
@article{Chen2024,
author = {Chen, Chen and Zhou, Xiaoyun and Gao, Xiaoxing and Pan, Ruili and He, Qi and Guo, Xiaobei and Yu, Siyuan and Wang, Na and Zhao, Qian and Wang, Mengzhao and Xu, Yan and Han, Xiaohong},
title = {Immune responses and reinfection of SARS‐CoV ‐2 Omicron variant in patients with lung cancer},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35038}
}
EUVIMED